Enterprise Value
437.1M
Cash
199.2M
Avg Qtr Burn
-31.68M
Short % of Float
3.06%
Insider Ownership
0.78%
Institutional Own.
83.77%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Ganaxolone (ZTALMY) Details Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder | Approved Quarterly sales | |
Ganaxolone Details Tuberous sclerosis complex | Phase 3 Data readout | |
Ganaxolone Details Epilepsy, Refractory Status Epilepticus | Phase 3 Data readout | |
Ganaxolone Details Established Status Epilepticus | Phase 2 Interim update | |
Second generation formulation Details Lennox-Gastaut syndrome | Phase 1 Interim update |